Rare Disease Report

Oncology

Catalyst Biosciences announced the initiation and open enrollment of the Phase 2 part of its Phase 2/3 program of marzeptacog alfa (activated), a highly potent, subcutaneously administered Factor VIIa therapy in development for the treatment of hemophilia A and B with inhibitors.
This morning, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Novatris’ eltrombopag (Promacta), a first-line treatment for severe aplastic anemia (SAA).
The U.S. FDA has accepted for review the New Drug Application for Azedra (iobenguane I 131) to be indicated for patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma.
Novartis announced that its combination therapy Tafinlar (dabrafenib) + Mekinist (trametinib) was granted Priority Review by the U.S. FDA for the adjuvant treatment of stage 3 BRAF V600 mutation-positive melanoma.
Last week, Novartis announced that the U.S. FDA approved the inclusion of Treatment-free Remission data in Tasigna (nilotinib).
This morning, the U.S. FDA granted regular approval to hydroxyurea for the treatment of pediatric patients from 2 years of age and older with sickle cell anemia with recurrent moderate to severe painful crises.
Pfizer has announced that the U.S. FDA approved a supplemental New Drug Application for Bosulif (bosutinib) to include patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia.
At the ASH Meeting and Exposition Martin Hutchings, Ph.D., M.D. discussed whether Adcetris is worth being investigated as a combination therapy.
Rare Disease Report sat down with Yutaka Niihara, M.D., MPH, to discuss the clinical trials for Endari, and when the drug will be available to patients.
At the 59th ASH Annual Meeting and Exposition, Rare Disease Report sat down with Clay Siegall to discuss why the plenary data presented over the weekend was so important to the rare cancer community.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.